The company had posted a net profit of Rs 63.93 crore during the same period of previous fiscal.
Net sales of the company stood at Rs 692.41 crore during the third quarter ended December 31, 2012. The company's net sales during the same period of previous fiscal stood at Rs 601.78 crore, Ipca Laboratories said in a filing to the BSE.
The results for the quarter ended December 31, 2012 are not comparable to the figures of same period of previous financial year due to the merger of Tonira Pharma with the company, it added.
During the period under review, the company's sales from domestic formulations business stood at Rs 212.73 crore, while the income from exports stood at Rs 442.37 crore.
Shares of Ipca Labs were trading at Rs 481 on the BSE in afternoon trade, down 1.40% from their previous close. PTI MSS STS tvs
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app